NIH R01 · 2024
SLC6A14 as a unique drug target to treat pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is lethal. Our laboratory has identified SLC6A14 to be highly upregulated in PDAC. SLC6A14 is a broad selective amino acid transporter with the ability to transport both essential and non-essential amino acids, which includes amino acids for mTORC1 activation, one-carbon moiety for DNA/histone methylation, and provide precursors for glutathione synthesis to counteract oxidative stress. We have already published using cell lines and xenograft mouse models that genetic deletion or pharmacological blockade of SLC6A14 attenuates PDAC growth by causing amino acid starvation and inhibition of mTORC1 signaling pathway. Using LSL-KrasG12D/+; LSL-p53R172H/+;…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.